The Effectiveness of Cucurbitacin B in BRCA1 Defective Breast Cancer Cells

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Promkan, Moltira ^a,b   Dakeng, Sumana ^a,c   Chakrabarty, Subhas ^b   Bögler, Oliver ^c   Patmasiriwat, Pimpicha ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

^b SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BRCA1 PROTEIN; CUCURBITACIN B; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; PACLITAXEL; SURVIVIN; UNCLASSIFIED DRUG;

ANCHORAGE INDEPENDENT GROWTH; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INVASION; CONTROLLED STUDY; DNA SEQUENCE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; MIGRATION INHIBITION; MOLECULAR DYNAMICS; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS; SEQUENCE ANALYSIS; TRICHOSANTHES; TRICHOSANTHES CUCUMERINA; TUMOR SUPPRESSOR GENE; WILD TYPE;

BLOTTING, WESTERN; BRCA1 PROTEIN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; HUMANS; TRITERPENES;

EID: 84873502084     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055732     Document Type: Article

References (59)

1. Chen JC, Chiu MH, Nie RL, Cordell GA, Qiu SX, (2005) Cucurbitacins and cucurbitane glycosides: structures and biological activities. Nat Prod Rep 22: 386-399.
2. Lee DH, Iwanski GB, Thoennissen NH, (2010) Cucurbitacin: ancient compound shedding new light on cancer treatment. Scientific World Journal 10: 413-418.
3. Efferth T, Kahl S, Paulus K, Adams M, Rauh R, et al. (2008) Phytochemistry and pharmacogenomics of natural products derived from traditional Chinese medicine and Chinese materia medica with activity against tumor cells. Mol Cancer Ther 7: 152-161.
4. Zhang M, Sun C, Shan X, Yang X, Li-Ling J, et al. (2010) Inhibition of Pancreatic Cancer Cell Growth by Cucurbitacin B Through Modulation of Signal Transducer and Activator of Transcription 3 Signaling. Pancreas 39: 923-929.
5. Agil A, Miró M, Jimenez J, Aneiros J, Caracuel MD, et al. (1999) Isolation of ani-hepatotoxic principle form the juice of Ecballium elaterium. Planta Med 65: 673-675.
6. Yasuda S, Yogosawa S, Izutani Y, Nakamura Y, Watanabe H, et al. (2009) Cucurbitacin B induces G(2) arrest and apoptosis via a reactive oxygen species-dependent mechanism in human colon adenocarcinoma SW480 cells. Mol Nutr Food Res 54: 559-565.
7. Lui VW, Yau DM, Wong EY, Ng YK, Lau CP, et al. (2009) Cucurbitacin I elicits anoikis sensitization, inhibits cellular invasion and in vivo tumor formation ability of nasopharyngeal carcinoma cells. Carcinogenesis 30: 2085-2094.
8. Sun C, Zhang M, Shan X, Zhou X, Yang J, et al. (2010) Inhibitory effect of cucurbitacin E on pancreatic cancer cells growth via STAT3 signaling. J Cancer Res Clin Oncol 136: 603-610.
9. Chan KT, Li K, Liu SL, Chu KH, Toh M, et al. (2010) Cucurbitacin B inhibits STAT3 and the Raf/MEK/ERK pathway in leukemia cell line K562. Cancer Lett 289: 46-52.
10. Thoennissen NH, Iwanski GB, Doan NB, Okamoto R, Lin P, et al. (2009) Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT pathway and potentiates antiproliferative effects of gemcitabine on pancreatic cancer cells. Cancer Res 69: 5876-5884.
11. Duncan KL, Duncan MD, Alley MC, Sausville EA, (1996) Cucurbitacin E-induced disruption of the actin and vimentin cytoskeleton in prostate carcinoma cells. Biochem Pharmacol 52: 1553-1560.
12. Blaskovich MA, Sun J, Cantor A, Turkson J, Jove R, et al. (2003) Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res 63: 1270-1279.
13. Farias MR, Schenkel EP, Mayer R, Rücker G, (1993) Cucurbitacins as Constituents of Wilbrandia ebracteata. Planta Med 59: 272-275.
14. Tannin-Spitz T, Grossman S, Dovrat S, Gottlieb HE, Bergman M, (2007) Growth inhibitory activity of cucurbitacin glucosides isolated from Citrullus colocynthis on human breast cancer cells. Biochem Pharmacol 73: 56-67.
15. Wakimoto N, Yin D, O'Kelly J, Haritunians T, Karlan B, et al. (2008) Cucurbitacin B has a potent antiproliferative effect on breast cancer cells in vitro and in vivo. Cancer Sci 99: 1793-1797.
16. Yang L, Wu S, Zhang Q, Liu F, Wu P, (2007) 23,24-Dihydrocucurbitacin B induces G2/M cell-cycle arrest and mitochondria-dependent apoptosis in human breast cancer cells (Bcap37). Cancer Lett 256: 267-278.
17. Duangmano S, Dakeng S, Jiratchariyakul W, Suksamrarn A, Smith DR, et al. (2010) Antiproliferative Effects of Cucurbitacin B in Breast Cancer Cells: Down-Regulation of the c-Myc/hTERT/Telomerase Pathway and Obstruction of the Cell Cycle. Int J Mol Sci 11: 5323-5338.
18. Lacroix M, Leclercq G, (2005) The "portrait" of hereditary breast cancer. Breast Cancer Res Treat 89: 297-304.
19. Tavtigian SV, Simard J, Rommens J, Couch F, Shattuck-Eidens D, et al. (1996) The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet 1: 333-337.
20. Welcsh PL, Owens KN, King MC, (2000) Insights into the functions of BRCA1 and BRCA2. Trends Genet 16: 69-74.
21. Gudmundsdottir K, Ashworth A, (2006) The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene 25: 5864-5874.
22. Deng CX, Wang RH, (2003) Roles of BRCA1 in DNA damage repair: a link between development and cancer. Hum Mol Genet 12: R113-23.
23. Patmasiriwat P, Bhothisuwan K, Sinilnikova OM, Chopin S, Methakijvaroon S, et al. (2002) Analysis of breast cancer susceptibility genes BRCA1 and BRCA2 in Thai familial and isolated early-onset breast and ovarian cancer. Hum Mutat 20: 230.
24. Szabo CI, Sinilnikova O, Badzioch M, Saxena S, Mukherjee A, et al. (2001) Mutation profile of BRCA1/2 mutations in world-wild populations: The MAGIC PROJECT. Proc Am Assoc Cancer Res 42.
25. James CR, Quinn JE, Mullan PB, Johnston PG, Harkin DP, (2007) BRCA1, a potential predictive biomarker in the treatment of breast cancer. Oncologist 12: 142-50.
26. Promkan M, Liu G, Patmasiriwat P, Chakrabarty S, (2009) BRCA1 modulates malignant cell behavior, the expression of survivin and chemosensitivity in human breast cancer cells. Int J Cancer 125: 2820-28.
27. Woods CM, Zhu J, McQueney PA, Bollag D, Lazarides E, (1995) Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway. Mol Med 1: 506-526.
28. Ireland CM, Pittman SM, (1995) Tubulin alterations in taxol-induced apoptosis parallel those observed with other drugs. Biochem Pharmacol 49: 1491-1499.
29. Fan W, (1999) Possible mechanisms of paclitaxel-induced apoptosis. Biochem Pharmacol 57: 1215-1221.
30. Khan S, Aspe JR, Asumen MG, Almaguel F, Odumosu O, et al. (2009) Extracellular, cell-permeable survivin inhibits apoptosis while promoting proliferative and metastatic potential. Br J Cancer 100: 1073-86.
31. Blagosklonny MV, (2005) Carcinogenesis, cancer therapy and chemoprevention. Cell Death Differ 12: 592-602.
32. Reynolds S, Cederberg H, Chakrabarty S, (2000) Inhibitory effect of 1-O (2 methoxy) hexadecyl glycerol and phenylbutyrate on the malignant properties of human prostate cancer cells. Clin Exp Metastasis 18: 309-312.
33. Kongtun S, Jiratchariyakul W, Kummalue T, Tan-ariya P, Kunnachak S, et al. (2009) Cytotoxic properties of root extract and fruit juice of Trichosanthes cucumerina. Planta Med 75: 839-842.
34. Elstrodt F, Hollestelle A, Nagel JH, Gorin M, Wasielewski M, et al. (2006) BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants. Cancer Res 66: 41-45.
35. Promkan M, Liu G, Patmasiriwat P, Chakrabarty S, (2011) BRCA1 suppresses the expression of survivin and promotes sensitivity to paclitaxel through the calcium sensing receptor (CaSR) in human breast cancer cells. Cell Calcium 49: 79-88.
36. Butler MS, (2004) The role of natural product chemistry in drug discovery. J Nat Prod 67: 2141-53.
37. Ma X, Wang Z, (2009) Anticancer drug discovery in the future: an evolutionary perspective. Drug Discov Today 14: 1136-1142.
38. Jiratchariyakul W, (1999) Cytotoxic principles from Trichosanthes cucumerina L. Thai J Phytopharm 6: 1-9.
39. Sun J, Blaskovich MA, Jove R, Livingston SK, Coppola D, et al. (2005) Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity. Oncogene 24: 3236-3245.
40. Lim CP, Phan TT, Lim IJ, Cao X, (2006) Stat3 contributes to keloid pathogenesis via promoting collagen production, cell proliferation and migration. Oncogene 25: 5416-5425.
41. Lui VW, Yau DM, Wong EY, Ng YK, Lau CP, et al. (2009) Cucurbitacin I elicits anoikis sensitization, inhibits cellular invasion and in vivo tumor formation ability of nasopharyngeal carcinoma cells. Carcinogenesis 30: 2085-2094.
42. Duangmano S, Sae-Lim P, Suksamrarn A, Domann FE, Patmasiriwat P, (2012) Cucurbitacin B inhibits human breast cancer cell proliferation through disruption of microtubule polymerization and nucleophosmin/B23 translocation. BMC Complement Altern Med 12: 185.
43. Atipairin A, Ratanaphan A, (2011) In Vitro Enhanced Sensitivity to Cisplatin in D67Y BRCA1 RING Domain Protein. Breast Cancer (Auckl) 5: 201-208.
44. Tassone P, Tagliaferri P, Perricelli A, Blotta S, Quaresima B, et al, (2003) BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer 88: 1285-1291.
45. Foulkes WD, Chappuis PO, Wong N, Brunet JS, Vesprini D, et al. (2000) Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome. Ann Oncol 11: 307-313.
46. Foulkes WD, Metcalfe K, Sun P, Hanna WM, Lynch HT, et al. (2004) Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res 10: 2029-2034.
47. Hosey AM, Gorski JJ, Murray MM, Quinn JE, Chung WY, et al. (2007) Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer. J Natl Cancer Inst 99: 1683-1694.
48. Dakeng S, Duangmano S, Jiratchariyakul W, U-Pratya Y, Bögler O, et al. (2012) Inhibition of Wnt signaling by cucurbitacin B in breast cancer cells: Reduction of Wnt-associated proteins and reduced translocation of galectin-3-mediated β-catenin translocation to the nucleus. J Cell Biochem 113: 49-60.
49. Wang C, Mayer JA, Mazumdar A, Fertuck K, Kim H, et al. (2011) Estrogen induces c-myc Gene Expression via an Upstream Enhancer Activated by the Estrogen Receptor and the AP-1 Transcription Factor. Mol Endocrinol 25: 1527-1538.
50. Greenberg RA, O'Hagan RC, Deng H, Xiao Q, Hann SR, et al. (1999) Telomerase reverse transcriptase gene is a direct target of c-Myc but is not functionally equivalent in cellular transformation. Oncogene 18: 1219-1226.
51. Wu KJ, Grandori C, Amacker M, Simon-Vermot N, Polack A, et al. (1999) Direct activation of TERT transcription by c-MYC. Nat Genet 21: 220-224.
52. Brown AM, (2001) Wnt signaling in breast cancer: have we come full circle? Breast Cancer Res 3: 351-355.
53. Polakis P, (2000) Wnt signaling and cancer. Genes Dev 14: 1837-1851.
54. Shimura T, Takenaka Y, Tsutsumi S, Hogan V, Kikuchi A, et al. (2004) Galectin-3, a novel binding partner of β-catenin. Cancer Res 64: 6363-67.
55. Shimura T, Takenaka Y, Fukumori T, Tsutsumi S, Okada K, et al. (2005) Implication of galectin-3 in Wnt signaling. Cancer Res 65: 3535-37.
56. Thompson C, MacDonald G, Mueller C, (2011) Decreased expression of BRCA1 in SK-BR-3 cells is the result of aberrant activation of the GABP beta promoter by an NRF-1-containing complex. Mol Cancer 10: 62.
57. Dubik D, Dembinski TC, Shiu RP, (1987) Stimulation of c-myc oncogene expression associated with estrogen-induced proliferation of human breast cancer cells. Cancer Res 47: 6517-6521.
58. Span PN, Sweep FC, Wiegerinck ET, Tjan-Heijnen VC, Manders P, et al. (2004) Survivin is an independent prognostic marker for risk stratification of breast cancer patients. Clin Chem 50: 1986-1993.
59. Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M, et al. (2000) Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 6: 127-134.